Display options
Cite
Schwan WR, Kolesar JM, Kabir MS, et al. Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92. Antibiotics (Basel). 2015;4(4):617-626doi: 10.3390/antibiotics4040617.
Schwan, W. R., Kolesar, J. M., Kabir, M. S., Elder, E. J., Williams, J. B., Minerath, R., Cook, J. M., Witzigmann, C. M., Monte, A., & Flaherty, T. (2015). Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92. Antibiotics (Basel, Switzerland), 4(4), 617-626. https://doi.org/10.3390/antibiotics4040617
Schwan, William R, et al. "Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92." Antibiotics (Basel, Switzerland) vol. 4,4 (2015): 617-626. doi: https://doi.org/10.3390/antibiotics4040617
Schwan WR, Kolesar JM, Kabir MS, Elder EJ, Williams JB, Minerath R, Cook JM, Witzigmann CM, Monte A, Flaherty T. Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92. Antibiotics (Basel). 2015 Dec;4(4):617-626. doi: 10.3390/antibiotics4040617. Epub 2015 Nov 24. PMID: 26877886; PMCID: PMC4748848.
Copy Download .nbib Format: NLM
Share it on

Antibiotics (Basel). 2015 Dec;4(4):617-626. doi: 10.3390/antibiotics4040617. Epub 2015 Nov 24.

Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92.

Antibiotics (Basel, Switzerland)

William R Schwan, Jill M Kolesar, M Shahjahan Kabir, Edmund J Elder, Jeffrey B Williams, Rachel Minerath, James M Cook, Christopher M Witzigmann, Aaron Monte, Tricia Flaherty

Affiliations

  1. Department of Microbiology, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA; Emerging Technology Center for Pharmaceutical Development, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA.
  2. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53706, USA.
  3. Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA.
  4. Zeeh Pharmaceutical Experiment Station, University of Wisconsin-Madison, Madison, WI 53705, USA.
  5. Department of Microbiology, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA.
  6. Emerging Technology Center for Pharmaceutical Development, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA; Department of Chemistry and Biochemistry, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA.

PMID: 26877886 PMCID: PMC4748848 DOI: 10.3390/antibiotics4040617

Abstract

Because of the potential of a new anti-staphylococcal lead compound SK-03-92 as a topical antibiotic, a patch, or an orally active drug, we sought to determine its safety profile and oral bioavailability. SK-03-92 had a high IC

Keywords: Staphylococcus; drug formulation; pharmacokinetics; safety testing

References

  1. J Pharm Biomed Anal. 2013 Jan;72:115-20 - PubMed
  2. J Pharm Biomed Anal. 2012 Jan 5;57:94-8 - PubMed
  3. JAMA. 2010 Aug 11;304(6):641-8 - PubMed
  4. BMC Infect Dis. 2014 Jun 02;14:296 - PubMed
  5. Pharm Res. 2004 Feb;21(2):201-30 - PubMed
  6. J Pharm Sci. 2011 Oct;100(10):4491-500 - PubMed
  7. J Infect Chemother. 2012 Feb;18(1):124-6 - PubMed
  8. Drug Metab Dispos. 2004 Dec;32(12):1377-82 - PubMed
  9. Free Radic Biol Med. 2002 Aug 1;33(3):387-98 - PubMed
  10. Pharm Res. 2008 Nov;25(11):2593-600 - PubMed
  11. Cancer Chemother Pharmacol. 2011 Sep;68(3):593-601 - PubMed
  12. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
  13. J Control Release. 2012 Oct 10;163(1):93-9 - PubMed
  14. J Agric Food Chem. 2009 Apr 22;57(8):3180-6 - PubMed
  15. Evid Based Complement Alternat Med. 2013;2013:261468 - PubMed
  16. Food Chem Toxicol. 2011 Dec;49(12):3319-27 - PubMed
  17. Mol Nutr Food Res. 2013 Jun;57(6):1015-25 - PubMed
  18. Clin Infect Dis. 2010 Apr 15;50(8):1081-3 - PubMed
  19. Clin Infect Dis. 2014 Jan;58 Suppl 1:S10-9 - PubMed
  20. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5745-9 - PubMed

Publication Types

Grant support